FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.
What happened
FDA reviewed website content at https://ybycmeds.com in August 2025 and observed that the site offers compounded drug products including semaglutide and tirzepatide. FDA found claims that these products are similar to Ozempic, Wegovy, Mounjaro, and Zepbound. FDA says the claims are false or misleading because compounded drug products are not FDA-approved.
What FDA found
FDA says the website claim that compounded semaglutide is similar to Ozempic or Wegovy is false or misleading because compounded drugs are not FDA-approved.
FDCA § 502(a) and § 502(bb), 21 U.S.C. §§ 352(a), 352(bb)FDA says the website claim that compounded tirzepatide is similar to Mounjaro or Zepbound is false or misleading because compounded drugs are not FDA-approved.
FDCA § 502(a) and § 502(bb), 21 U.S.C. §§ 352(a), 352(bb)FDA says the claims imply the products are the same as FDA-approved products when they are not.
FDCA § 502(a) and § 502(bb), 21 U.S.C. §§ 352(a), 352(bb)FDA says introducing these drugs into interstate commerce is prohibited because their advertising is false or misleading.
FDCA § 301(a), 21 U.S.C. § 331(a)FDA says receiving or delivering these misbranded drugs in interstate commerce is also prohibited.
FDCA § 301(c), 21 U.S.C. § 331(c)
What FDA wants
FDA tells ybycmeds to take immediate action, including ceasing and desisting from using the misleading language, and to respond in writing within 15 working days describing steps taken to address the violations and prevent recurrence.
Who should pay attention
- online sellers and telehealth sites offering compounded semaglutide or tirzepatide
- compounding pharmacies that compare their products to brand-name drugs
- weight-loss clinics and brands marketing compounded drugs
This is a summary. Read the original letter on fda.gov.